Otsuka Holdings Raises H1 FY2026 Profit Forecast 66% on Drug Sales Strength
Otsuka Holdings Co., Ltd. (TSE:4578) raised its interim earnings guidance for the first half of fiscal 2026 ending June 30, citing robust pharmaceutical sales and delayed generic competition in key markets.
| Item | Before | After | Change |
|---|---|---|---|
| 売上収益 | JPY 1218.0bn | JPY 1332.0bn | +9.4% |
| 事業利益 | JPY 173.0bn | JPY 280.0bn | +61.8% |
| Operating Profit | JPY 175.0bn | JPY 278.0bn | +58.9% |
| 税引前中間利益 | JPY 172.0bn | JPY 285.0bn | +65.7% |
| 中間利益 | JPY 131.0bn | JPY 218.0bn | +66.4% |
| 親会社の所有者に帰属する中間利益 | JPY 128.0bn | JPY 215.0bn | +68.0% |
| 基本的１株当たり中間利益 | JPY 243M | JPY 408M | +67.8% |
The company attributed the upward revision to stronger-than-expected performance in its pharmaceutical division, where key products including the anti-APRIL antibody Vobaxtart, antipsychotic Rexulti, and anticancer agent Lonsurf posted solid gains. Additionally, generic entry delays for U.S. Zinacef and European Abilify Maintena extended patent protection longer than initially forecast. The revision also reflects favorable currency effects from yen weakness against the dollar and euro. Partially offsetting these gains, Otsuka suspended development of certain Urotarlon indications and expects lower research and development spending due to timing shifts in project expenditures.
The interim profit guidance now implies a 66–68% increase in net income attributable to parent shareholders, with earnings per share rising 67.8% to JPY 408.00/share. The revision signals resilience in Otsuka’s core pharmaceutical business despite competitive pressures, supported by blockbuster drug momentum and favorable macroeconomic conditions. Investors should monitor full-year guidance updates and pipeline progress on development-stage candidates.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.